ORLANDO, FL / ACCESSWIRE / March 8, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced that it has joined Webull's Corporate Communications Service Platform, which will provide Nutriband with a comprehensive suite of investor relations and corporate communications solutions. This will enable Nutriband to enhance its corporate communications efforts, expand its investor outreach, and increase its visibility among potential investors.
Nutriband's portal on the Webull Platform will help provide the Company with a direct line of communication to shareholders and followers by providing instant notifications regarding corporate content such as company news, earnings reports, investor presentations, and more.
Nutriband's CEO, Gareth Sheridan, stated, "We are pleased to join Webull's Corporate Communications Service Platform and to take advantage of their advanced investor relations and corporate communications solutions. This platform will help us to better engage with current and potential future shareholders, providing them with the timely and accurate information they need to make informed investment decisions."
To follow Nutriband, current Webull users can visit:https://www.webull.com/quote/nasdaq-ntrb. For more information and to create a Webull account, please visit: webull.com
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA abuse deterrence technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words 'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, the risk that prior clinical results may not be replicated in future studies and trials (including the risk that the clinical results from the Phase 1b study might not be replicated), as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Annual Report on Form 10-K for the year ended January 31, 2022 and subsequent Quarterly Reports on Form 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
For more information, contact:
Investor Relations
RedChip Companies
Dave Gentry
Dave@redchip.com
1-800-RED-CHIP (733-2447)
407-491-4498
SOURCE: Nutriband Inc.
View source version on accesswire.com:https://www.accesswire.com/742618/Nutriband-Inc-Joins-Webull-Corporate-Communications-Service-Platform
